Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (NASDAQ:NTLA) will announce its first quarter 2022 financial results on May 5, 2022, at 8 a.m. ET. The company, a leader in genome editing focused on CRISPR technology, will discuss operational highlights during a conference call. U.S. participants can dial 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will also be available. Post-call, a replay will be accessible on Intellia’s website.
Intellia Therapeutics (NASDAQ: NTLA) announced that its investigational T cell receptor (TCR)-T cell therapy, NTLA-5001, has received orphan drug designation from the FDA for treating acute myeloid leukemia (AML). This therapy targets the Wilms’ Tumor 1 (WT1) antigen, prevalent in AML and other cancers. Currently in a Phase 1/2a clinical trial, NTLA-5001 aims to provide new treatment options for patients with recurrent AML. The orphan status supports development incentives, including potential market exclusivity and tax credits.
Intellia Therapeutics (NTLA) has announced the dosing of the first patient with NTLA-5001, an investigational T cell receptor (TCR) therapy aimed at treating acute myeloid leukemia (AML). This CRISPR/Cas9 engineered therapy targets the Wilms' Tumor 1 (WT1) antigen, frequently found in AML and other cancers. The Phase 1/2a study will assess the therapy's safety, efficacy, and anti-tumor activity. The trial has two arms, focusing on AML patients with varying disease burdens. With over 20,000 new AML cases annually in the U.S., NTLA-5001 represents a significant advancement in cancer treatment.
On February 28, 2022, Intellia Therapeutics and Regeneron Pharmaceuticals announced promising interim results from a Phase 1 clinical trial of NTLA-2001 for treating transthyretin amyloidosis (ATTR). The study demonstrated a mean serum TTR reduction of 93% at the highest dose (1.0 mg/kg) by day 28, with durable reductions lasting between two to twelve months. The treatment was generally well tolerated, with mild adverse effects reported. The companies plan to advance the therapy into a dose-expansion cohort in Q1 2022, marking a significant step in CRISPR-based genomic medicine.
Intellia Therapeutics announced promising interim results from a Phase 1 trial of NTLA-2001, aimed at treating transthyretin (ATTR) amyloidosis. A mean serum TTR reduction of 93% was achieved at the 1.0 mg/kg dose by day 28, with durable effects sustained for 2 to 12 months. The treatment was generally well tolerated, with most adverse events mild. NTLA-2001 is the first CRISPR-based therapy administered systemically, marking a significant advancement in genome editing. Intellia plans to initiate a polyneuropathy dose-expansion cohort in Q1 2022 and will host an investor event to discuss these findings.
Intellia Therapeutics (NASDAQ: NTLA) reported its Q4 2021 results, showcasing significant growth and strategic advancements in its CRISPR-based pipeline. The company plans to present additional interim data from its Phase 1 study on NTLA-2001 for ATTR amyloidosis on February 28, 2022. Notably, Intellia announced two new candidates, NTLA-6001 for hematologic cancers and NTLA-2003 for liver-related AATD. With $1.086 billion in cash as of year-end 2021, up from $597.4 million in 2020, Intellia is well-positioned for future developments. Net loss rose to $81.2 million, emphasizing the costs of advancing multiple clinical programs.
Intellia Therapeutics (NASDAQ:NTLA) has announced a lease agreement for a new 140,000-square-foot GMP manufacturing facility in Waltham, Massachusetts, expected to be operational in 2024. This facility will support the production of components for its CRISPR-based investigational therapies, enhancing manufacturing capacity and capability as the company advances its pipeline. Intellia's Chief Technical Officer emphasized the strategic importance of this investment for efficient production, while the Chief Financial Officer noted the benefits of a long-term lease over building a facility.
Intellia Therapeutics (NASDAQ:NTLA) has announced two virtual investor events in February 2022. The first is the Fourth Quarter and Full-Year 2021 Financial Results, scheduled for February 24 at 8:00 a.m. ET. U.S. callers can dial 1-833-316-0545 to join. The second event is an update on interim clinical data for NTLA-2001, set for February 28 at 4:30 p.m. ET, featuring presentations from leading experts. NTLA-2001 aims to treat ATTR amyloidosis using CRISPR technology, potentially allowing for a single-dose treatment option.
Intellia Therapeutics (NTLA) and ONK Therapeutics have entered a collaboration to develop CRISPR-edited NK cell therapies for cancer treatment. ONK receives non-exclusive rights to Intellia's ex vivo genome editing and delivery technologies for up to five therapies, while Intellia is eligible for $184 million per product in milestone payments and royalties. The agreement allows for co-development of two therapies, with Intellia holding lead commercialization rights in the U.S. This collaboration aims to enhance NK cell efficacy against various cancers.
Intellia Therapeutics (NASDAQ:NTLA) announced its acquisition of Rewrite Therapeutics for $45 million upfront, plus up to $155 million in milestones. This strategic acquisition enhances Intellia's genome editing capabilities, integrating Rewrite's novel DNA writing platform. Rewrite’s technology promises precise gene editing solutions, including targeted corrections and edits in non-dividing cells, facilitating potential advancements in genomic medicine. The merger is expected to expand Intellia’s therapeutic applications, aligning with its mission to develop curative CRISPR-based therapeutics.